Jpmorgan Chase & CO Spruce Biosciences, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SPRB
# of Institutions
34Shares Held
15.4MCall Options Held
16.7KPut Options Held
1.1K-
River Vest Venture Management LLC St. Louis, MO2.94MShares$1.47 Million20.39% of portfolio
-
Carlyle Group Inc. Washington, DC2.9MShares$1.45 Million0.2% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.61MShares$1.3 Million0.04% of portfolio
-
Abingworth LLP London, X01.79MShares$896,2590.65% of portfolio
-
Acadian Asset Management LLC Boston, MA1.26MShares$629,5750.0% of portfolio
About SPRUCE BIOSCIENCES, INC.
- Ticker SPRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,560,200
- Market Cap $11.8M
- Description
- Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...